HAS recommendation on the place of a booster with the COMIRNATY mRNA vaccine

On October 4, 2021, the COMIRNATY® vaccine obtained a variation to the conditional marketing authorization (MA) in Europe (centralized procedure) and can be administered as a booster dose (3rd dose), injected by the route intramuscularly at least 6 months after the second dose, in persons aged 18 years and over.

In short:

• The update of the most recent data confirms the HAS recommendations of 23 August 2021, relating to the administration of a booster dose for people 65 years of age and over, as well as for all people with Co-morbidities increasing the risk of severe forms and death linked to Covid-19.
• Given the increased risk of exposure and infection to the SARS-CoV-2 virus compared to the general population, the HAS recommends extending the administration of a booster dose to professionals in the health sector. health and the medico-social sector, in contact with patients and with medical transport professionals. Indeed, these professionals are both more exposed and more likely to transmit the disease through their direct contact with patients, so the booster dose is intended to give them the best possible protection against the Delta variant, which is more transmissible, and to contribute, by limiting the spread of the disease, to the protection of the vulnerable people they care for.
• The HAS also recommends, with the same objective, to carry out a booster dose in people close to immunocompromised people (cocooning strategy) only in adults aged over 18 years (in accordance with the modification of the SPC of the vaccine Comirnaty ).